Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Exciting advances in the field of CLL

Christine Ryan • 10 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab

Christine Ryan, MD, Dana-Farber Cancer Institute, Boston, MA, shares her excitement for advances in targeted therapies for chronic lymphocytic leukemia (CLL), including next-generation BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Christine Ryan

0:33
The management of elderly patients with CLL
Christine Ryan • 10 Jun 2022
2:58
Results of a Phase Ib study of ibrutinib + obinutuzumab in R/R CLL
Christine Ryan • 10 Jun 2022

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals